Jun 03, 2019 - Merck (MRK) presents longest follow-up data for Keytruda in advance lung cancer at ASCO 2019. The five-year overall survival rates in the Keytruda arm are better than historical rates
May 31, 2019 - The index endured another tough week as investors braced for an economic slowdown.
May 28, 2019 - And the analyst really likes one in particular.
May 27, 2019 - Pfizer (PFE) announces failure of a phase III study evaluating Lyrica in patients with primary generalized tonic-clonic seizures, a form of epilepsy.
May 24, 2019 - We highlight three stocks that are using innovative ways to treat cancer, also called malignancy. These stocks are also great long-term investments.
May 21, 2019 - Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.
May 17, 2019 - FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
May 16, 2019 - Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.
May 15, 2019 - Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
May 10, 2019 - Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.